RxDoctor Payments Data

Justin Marone, DO

Procedural Dermatology · Owosso, MINPI 1104857796

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.6% of the total across 283 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations.

$6,105in general payments, 2019–2025

Across 283 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$720
  • Novartis$613
  • Lilly USA, LLC$515
  • Amgen$508
  • Boehringer Ingelheim$296
  • plus $2K from 23 others

What the payments were for

  • Food & beverage$5,65593%
  • Education$4507%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few procedural dermatology providers in Michiganto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$212,519
Medicare patients
272
Services billed
6,659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept13$93,566
Cosentyx Sensoready (2 Pens)Secukinumab11$81,914
OtezlaApremilast14$63,380
Clobetasol EmollientClobetasol Propionate/Emoll38$3,144
Triamcinolone Acetonide200$1,705
Fluocinonide-EFluocinonide/Emollient Base19$1,466
Doxycycline Hyclate125$1,442
Ketoconazole77$1,438
Fluocinonide22$1,416
Betamethasone Dipropionate25$932
Minocycline Hcl19$889
Hydrocortisone Valerate44$878
Gentamicin Sulfate47$748
Mupirocin68$584
Halobetasol Propionate13$575

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$508$63,38014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few procedural dermatology providers in Michiganon file to place this against a meaningful peer group, so we don't.

Other procedural dermatology in Owosso

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →